News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Next-generation sequencing implementation in Mexican adults with acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
Key Points Automated NGS in Mexico reveals a distinct AML profile with high Fms-like tyrosine kinase 3 mutations and few age-related variants. AML risk assessment improved via genomics but survival was limited by restricted access to targeted therapies and HCT. Abstract…

Dr. Valeria Santini gives overview of SOHO 2026 MDS session 

Original Publication Date
Article Source
External Web Content
Valeria Santini, MD, discusses advances in the treatment of myelodysplastic syndromes, including new therapeutic options for patients with lower-risk disease. “We do not only want to improve the quality of life, but also prolong survival,” Dr. Santini said. In addition to…

Endotheliopathy and VWF-ADAMTS13 axis dysfunction in VEXAS thrombogenicity

Original Publication Date
Article Source
External Web Content
Key Points VEXAS syndrome is associated with endothelial cell activation, endotheliopathy and VWF-ADAMTS13 axis dysfunction. Increased plasma FVIII levels, enhanced thrombin generation and activated protein C resistance are thrombogenic features of VEXAS. Markedly increased risk…

Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation

Original Publication Date
Article Source
External Web Content
HIGHLIGHTS - Prophylactic rituximab reduces EBV infection and PTLD in high-risk allo-HCT recipients. - IPTW and Fine–Gray analyses confirm an independent reduction in EBV infection risk. - Despite delayed B-cell recovery, IgG levels and first-year IVIG use remain comparable…

How Interferon Changes Cancerous Blood Stem Cells

Original Publication Date
Article Source
External Web Content
The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of…

Type 1 interferon perturbates clonal competition by reshaping human blood development

Original Publication Date
Article Source
External Web Content
Abstract Inflammation accelerates evolutionary dynamics of hematopoietic stem cells (HSCs) in clonal hematopoiesis and myeloid neoplasms. We studied HSCs, progenitors and immune cells from patients with myeloproliferative neoplasms at baseline and following interferon-α (IFNα)…

Treatment of Severe Acute Graft-Versus-Host Disease Refractory to Multiple Lines of Therapy: Real-World Data from 317 Adults Treated with the Multiple-Donor Bone Marrow-Derived Mesenchymal Stromal Cell Preparation Tomostrocel

Original Publication Date
Article Source
External Web Content
Highlights - Tomostrocel is a multi-donor bone marrow-derived MSC product in late-stage development - Real-world data of 317 adult aGvHD patients treated with tomostrocel are analyzed - 75% of patients had prior ruxolitinib, >90% had grade III/IV and/or lower GI-aGvHD - The Day…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families